Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept
journal contributionposted on 23.01.2014 by Kate S. Ashton, Kristin L. Andrews, Marion C. Bryan, Jie Chen, Kui Chen, Michelle Chen, Samer Chmait, Michael Croghan, Rod Cupples, Christopher Fotsch, Joan Helmering, Steve R. Jordan, Robert J. M. Kurzeja, Klaus Michelsen, Lewis D. Pennington, Steve F. Poon, Glenn Sivits, Gwyneth Van, Steve L. Vonderfecht, Robert C. Wahl, Jiandong Zhang, David J. Lloyd, Clarence Hale, David J. St. Jean
Any type of content formally published in an academic journal, usually following a peer-review process.
Small molecule activators of glucokinase have shown robust efficacy in both preclinical models and humans. However, overactivation of glucokinase (GK) can cause excessive glucose turnover, leading to hypoglycemia. To circumvent this adverse side effect, we chose to modulate GK activity by targeting the endogenous inhibitor of GK, glucokinase regulatory protein (GKRP). Disrupting the GK-GKRP complex results in an increase in the amount of unbound cytosolic GK without altering the inherent kinetics of the enzyme. Herein we report the identification of compounds that efficiently disrupt the GK-GKRP interaction via a previously unknown binding pocket. Using a structure-based approach, the potency of the initial hit was improved to provide 25 (AMG-1694). When dosed in ZDF rats, 25 showed both a robust pharmacodynamic effect as well as a statistically significant reduction in glucose. Additionally, hypoglycemia was not observed in either the hyperglycemic or normal rats.